Prometheus to acquire rights to GlaxoSmithKline’s Lotronex

Prometheus will market and sell Lotronex under an exclusive distribution agreement until the acquisition is completed, which is expected in January 2008. Prometheus will continue to offer Lotronex exclusively through the currently established prescribing program for Lotronex (PPL). Lotronex may be prescribed only by physicians who have enrolled in the PPL.

Lotronex is the only prescription drug approved by the FDA for use in women with severe diarrhea-predominant irritable bowel syndrome.

Joseph Limber, president and CEO of Prometheus, said: “The acquisition of Lotronex is a significant opportunity for Prometheus and an important next step in continuing to build our portfolio of proprietary pharmaceutical products. Lotronex fits well with our long-term plans to grow through acquisitions of meaningful therapeutic products and enhances Prometheus’s position as a leading provider of therapeutics and diagnostics for physicians and their patients who suffer from severe gastrointestinal diseases.”